Q2 FY27 · NSE: MOREPENLAB
Morepen Laboratories
Results filed 27 October 2026 · Market cap ₹6,211 crore · PE 32.9
- Revenue
- +81.4%
- on a year ago
- EBITDA
- +301.0%
- on a year ago
- Profit to shareholders
- +117.5%
- on a year ago
- EBITDA margin
- 16.5%
- +2.0 pts on last quarter
| Q2 FY27 | Q1 FY27 | vs previous quarter | Q2 FY26 | vs a year ago | |
|---|---|---|---|---|---|
| Revenue | 747 | 570 | +30.9% | 412 | +81.4% |
| Operating profit (EBIT) | 113 | 74.19 | +52.4% | 19.42 | +482.1% |
| Operating margin | 15.1% | 13.0% | +213 bps | 4.7% | +1042 bps |
| Other income | 8.69 | 5.18 | +67.8% | 4.64 | +87.3% |
| Exceptional items | 0 | 0 | – | 25.83 | – |
| Profit before exceptional items and tax | 117 | 74.53 | +56.4% | 19.87 | +486.5% |
| Profit to shareholders | 88.89 | 56.4 | +57.6% | 40.87 | +117.5% |
| Share of joint ventures' and associates' profit | 0 | 0.05 | −100.0% | −0.17 | n.m. |
| Earnings per share (₹) | 1.62 | 1.03 | +57.3% | 0.75 | +116.0% |
Source: Morepen Laboratories Limited’s filing to NSE, 27 October 2026. Operating profit is revenue less every expense except interest, so it leaves out other income and exceptional items. n.m.: not meaningful, because the earlier figure was zero or negative, or the latest one is a loss.
Notes
No notes yet. They are written once the investor presentation or concall transcript is filed; transcripts usually come three to seven days after the call.
Sources
- Investor presentation · filed Oct
- Figures: the company’s results filing with NSE, linked under the table.